Partner with EsoCap

We have demonstrated technical functionality, clinical efficacy in eosinophilic esophagitis (EoE) and industrial scale-up capability. We are now actively seeking commercial partners for our lead product ESO-101, which offers a unique innovative approach to the treatment of EoE in a large, fast-growing market.

The EsoCap technology is a highly attractive partnering target for biopharmaceutical companies in many strategic areas, such as gastroenterology, immunology, oncology, rare diseases, drug delivery, and CDMOs (contract development and manufacturing organisations).

Investors

If you’d like to find out more about solving the problem of EoE patients or discuss investment opportunities in EsoCap, please let us know by filling in the form.

Existing Cooperations

The company has forged strategic partnerships with university researchers, KOLs (Key Opinion Leaders) and industry partners to achieve its goal. The aim is to make our therapies accessible to EoE patients, improving their health and quality of life as soon as possible.

EsoCap AG has a particularly fruitful cooperation with the University of Greifswald, where the EsoCap technology was invented by Prof. Werner Weitschies, Head of the Center of Drug Absorption and Transport at the Institute of Pharmacy, University of Greifswald, Germany, and his team.

Across numerous departments and disciplines, the University of Greifswald community advances ideas and innovations that enrich human life. The University’s departments encompass a wide range of fields, including General and Clinical Pharmacology, Biopharmaceutics and Pharmaceutical Technology, Pharmaceutical Biotechnology, and all clinical disciplines. The Center of Drug Absorption and Transport (C_DAT) is an internationally recognized center of expertise in which research groups of the University of Greifswald and the University Medical Center Greifswald investigate the processes of absorption and transport of drugs through to their desired – or unwanted – sites of effect in the human body.

The C_DAT is respected worldwide and is the leading center of excellence for drug absorption and transport in Europe.

EsoCap AG and LTS Lohmann Therapy-Systeme AG cooperate on industrial development and manufacture of clinical trial samples for EsoCap’s unique drug delivery technology for diseases of the upper gastrointestinal tract.

This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology. 

LTS is a leading pharmaceutical technology company that develops and manufactures innovative thin film drug delivery systems for the pharmaceutical industry. LTS´s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, New Jersey, USA, with a representation in Shanghai, China.

EsoCap AG and LTS Lohmann Therapy-Systeme AG cooperate on industrial development and manufacture of clinical trial samples for EsoCap’s unique drug delivery technology for diseases of the upper gastrointestinal tract.

This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology. 

LTS is a leading pharmaceutical technology company that develops and manufactures innovative thin film drug delivery systems for the pharmaceutical industry. LTS´s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, New Jersey, USA, with a representation in Shanghai, China.

Lonza’s Capsules & Health Ingredients business is a trusted partner in innovative capsules, dosage form solutions and health ingredients for pharmaceutical and nutraceutical companies. Their business has grown through the acquisition of Capsugel and InterHealth Nutraceuticals.
The unique combination of science, engineering, ingredient and formulation expertise and capsule polymer science enables their customers to optimize bioavailability, provide targeted delivery and overall excel in the performance of their pharmaceutical and nutraceutical products. Lonza`s reputation for capsule expertise and research-backed ingredients has connected them with more than 5,000 customers in over 100 countries.